共查询到20条相似文献,搜索用时 62 毫秒
1.
本大型专著是中国蛇协急危重症医学研究所蓝海医师与中国科学院上海生物化学研究所陈远聪研究员共同主编,集国内外50余位专家、教授的智慧,详细介绍了近年来对毒蛇、蛇毒、蛇伤的最新研究成果。由中国医学科学院、中国协和医科大学吴崇其研究员作“序”,定于今年上半年由上海科技出版社出版发行。现介绍本书的九大特点大型专著《中国毒蛇及蛇伤救治》九大特点$中国蛇协急危重症医学研究所@李金荣
$中国蛇协急危重症医学研究所@蓝海 相似文献
2.
3.
毒蛇咬伤是我国(尤其南方地区)危害性极高的常见病.据不完全统计,我国每年蛇伤病例占18~30万.被毒蛇咬伤后,发病急,发展凶险,如不及时处理或救治不当,常危及生命.对我边防战士、在田野上耕作的农民兄弟、野外勘探工作人员、林业建设人员、城乡居民的生命健康构成威胁.国防建设、工农业生产及人民群众安居乐业,均受到一定的影响.不少人"谈蛇色变". 相似文献
4.
5.
6.
7.
由亚洲蛇伤防治学会、湛江市临床医学研究所共同发起和组织的第一届国际蛇伤学术研讨会,于1997年10月15~19日在中国广东省湛江市召开。会议收到论文186篇,其中包括来自俄罗斯等24个国家和地区的论文36篇;出席会议代表136人,其中国外代表4人。会... 相似文献
9.
俗话说,谈蛇色变。谈起蛇,我又害怕,又喜欢,孩童时不敢走夜路,怕被蛇咬,中学毕业后,羡慕抓蛇人,还抓过蛇,玩过蛇,对蛇医更是崇拜得五体投地。在日本攻读博士时,天天和蛇毒打交道,研究蛇毒与凝血出血的关系,由此还结识了许多研究蛇的海内外专家,所以我对蛇还是比较有感情的。当副校长期间还带团考察世界最大的蛇毒研究基地:巴西布丹丹(Butatan Instisute),深感对蛇的研究大有学问可做。 相似文献
10.
11.
蛇伤溃疡是国内外蛇伤防治领域的一个研究热点,也是临床外科多年来的研究课题.治疗毒蛇咬伤,不仅要抢救生命,还要认真保护肢体的完整及功能.蛇伤后伤口感染或化脓,组织坏死,溃疡久治不愈引起的肢体畸形、残废,目前在国内外还是比较棘手的一大难题.我院经过多年的潜心研究,制成蛇创溃疡散.该药用于治疗376例蛇伤溃疡患者,治愈率达91.5%,总有效率为97.6%[1].由于该药的应用,使我院蛇伤后残肢率明显下降,使许多患者免除了截肢(终身残废)的痛苦.蛇创溃疡散的科研成果已被中国中医药学会、中国中医研究院确认,为此谨就蛇伤溃疡的诊断,治疗和预防等有关问题概述如下. 相似文献
12.
广西的蛇类资源与蛇伤调查 总被引:1,自引:3,他引:1
报道作者在广西壮族自治区 (中国的一个省 )进行蛇类资源和蛇咬伤情况的调查结果。至今为止发现栖息在广西境内的蛇类有 7科 4 2属 96种 ,其中盲蛇科( Typhloidae)、 1种、蟒科 ( Boidae) 1种、闪鳞蛇科( Xenopheltidae) 1种、游蛇科 ( Colubridae) 71种、眼镜蛇科 ( Elapidae) 6种、海蛇科 ( Hydrophiidae) 7种、蝰科( Viperidae) 9种 ,其中有毒蛇 33种。经蛇伤流行病学调查推算 ,广西每年蛇伤病人约 376 0 0例 ,其中约 1 0 1 9例死亡 ,而蛇伤死亡率最高为眼镜王蛇咬伤 ( 5 7.1 % ) ;其次为银环蛇 ,由于抗蛇毒血清供应不足 ,很多边远地区病人因不能及时接受抗蛇毒血清治疗是造成死亡的主要原因之一。 相似文献
13.
14.
蛇伤性肢体溃疡的治疗进展 总被引:1,自引:1,他引:0
混合毒类毒蛇和血循毒类毒蛇的蛇毒中含有丰富的血循毒素,卵磷脂酶A、透明质酸酶、蛋白水解酶等毒性物质,进入人体后对组织产生严重损害,尤其是对微血管的内皮细胞、细胞的膜系统,增强管壁的通透性,以致发生组织水肿、坏死性炎症,甚至直接作用于肌纤维,导致肌纤维的断裂,从而形成溃疡和组织坏死,严重时坏死可深达骨膜,使肌腱和骨骼外露。中医认为, 相似文献
15.
16.
目的探讨毒蛇咬伤早期集束化治疗对病情的影响。方法收集我院2011年4月~2014年11月资料完整的70例五步蛇咬伤患者的临床资料,统计分析患者的就诊时间、清洗伤口时间、伤口切开时间、使用抗蛇毒血清时间、使用激素时间与病情严重程度、肢体肿胀程度及住院时间的关系。结果就诊时间、清洗伤口时间、伤口切开时间、使用抗蛇毒血清时间、使用激素时间与病情严重程度、肢体肿胀程度及住院时间明显相关(均P0.001)。以各指标中位数为截点进行危险分层,大于中位数组的病情严重程度、肢体肿胀程度重于小于中位数组,大于中位数组的住院时间长于小于中位数组,差异具有统计学意义(均P0.01)。结论毒蛇咬伤预后受多因素影响,在短时间内完成集束化治疗可减轻病情严重程度及缩短住院时间,改善预后。 相似文献
17.
中西医结合治疗毒蛇咬伤773例 总被引:5,自引:2,他引:3
目的:探讨中西医结合治疗各类型毒蛇咬伤的临床方法。方法根据1964-1998年收治各类型毒蛇咬伤患者773例的临床资料,分析中草药、西医综合对症治疗及灵活应用抗蛇毒血清的临床疗效。结果治愈765例,治愈率99.0%;死亡8例,死亡率。结果治愈765例,治愈率99.0%;死亡8例,死亡率1.0%。结论建立完善的抢救治疗队伍,采用中西医结合的综合性治疗方法,可明显提高临床治愈率。 相似文献
18.
目的探讨我国华南亚种眼镜蛇(Naja naja atra)咬伤所致局部损伤的特点和治疗体会。方法回顾我院收治的102例眼镜蛇咬伤病人的相关资料,观察比较受伤局部损伤情况和临床表现以及治疗方法与疗效等情况。结果所有病例均表现为牙痕周围组织不同程度的坏死和周边较大范围的炎症反应和局域淋巴结肿大,部分病例伴有或发热、困倦以及血WBC增高等表现,少数病例出现心、肝、肾功能轻度损害和溶血表现,未见典型神经麻痹病例和凝血功能障碍病例;84例实施了清创术,28病例实施了植皮手术,9例实施了筋膜室切开减压,2例实施了截肢术,所有病例在(17±6.2)天内痊愈,致残5例,无死亡病例。结论华南亚种眼镜蛇咬伤的特点是局部组织变性坏死,神经毒和血液循环毒方面的表现轻而少见,早期使用抗眼镜蛇毒血清是预防和减少局部组织损伤的的关键措施,在此基础上,及时清除坏死组织、积极抗炎消肿减压、尽早植皮覆盖创面对抑制局部损伤发展和促进组织修复以及加快痊愈有重要意义。 相似文献
19.
Venomous snakebite is considered the single most important cause of human injury from venomous animals worldwide. Coagulopathy is one of the commonest important systemic clinical syndromes and can be complicated by serious and life-threatening haemorrhage. Venom-induced consumption coagulopathy (VICC) is the commonest coagulopathy resulting from snakebite and occurs in envenoming by Viperid snakes, certain elapids, including Australian elapids, and a few Colubrid (rear fang) snakes. Procoagulant toxins activate the clotting pathway, causing a broad range of factor deficiencies depending on the particular procoagulant toxin in the snake venom. Diagnosis and monitoring of coagulopathy is problematic, particularly in resource-poor countries where further research is required to develop more reliable, cheap clotting tests. MEDLINE and EMBASE up to September 2013 were searched to identify clinical studies of snake envenoming with VICC. The UniPort database was searched for coagulant snake toxins. Despite preclinical studies demonstrating antivenom binding toxins (efficacy), there was less evidence to support clinical effectiveness of antivenom for VICC. There were no placebo-controlled trials of antivenom for VICC. There were 25 randomised comparative trials of antivenom for VICC, which compared two different antivenoms (ten studies), three different antivenoms (four), two or three different doses or repeat doses of antivenom (five), heparin treatment and antivenom (five), and intravenous immunoglobulin treatment and antivenom (one). There were 13 studies that compared two groups in which there was no randomisation, including studies with historical controls. There have been numerous observational studies of antivenom in VICC but with no comparison group. Most of the controlled trials were small, did not use the same method for assessing coagulopathy, varied the dose of antivenom, and did not provide complete details of the study design (primary outcomes, randomisation, and allocation concealment). Non-randomised trials including comparison groups without antivenom showed that antivenom was effective for some snakes (e.g., Echis), but not others (e.g., Australasian elapids). Antivenom is the major treatment for VICC, but there is currently little high-quality evidence to support effectiveness. Antivenom is not risk free, and adverse reactions can be quite common and potentially severe. Studies of heparin did not demonstrate it improved outcomes in VICC. Fresh frozen plasma appeared to speed the recovery of coagulopathy and should be considered in bleeding patients. 相似文献
20.
To investigate the therapeutic efficacy of sustained low-efficiency dialysis (SLED) in severe snakebite patients. Fifteen patients of severe snakebite was treated with SLED from July 2005 to August 2009 were included in the study. Central venous access was established in all patients. SLED was administered using Dialog+ dialyzer (B. Braun, Germany). SLED sessions were 6–12 h in duration at a blood flow rate of 200 ml/min and a dialysate flow rate of 300 ml/min. Heparin or low molecular weight heparin was used as anticoagulant. Biochemical indicators, APACHE II scores before and after SLED, and clinical outcomes were evaluated. The levels of serum creatinine, glutamic-oxaloacetic transaminase, glutamic-pyruvic transaminase, creatine kinase isozyme MB, and creatine kinase were significantly lower than the level before SLED (P < 0.05); the level of cholinesterase was significantly higher after SLED (P < 0.01); the APACHE II score before SLED was 14.1 ± 3.8, but decreased significantly to 7.9 ± 1.4, 6.2 ± 1.1, and 4.2 ± 0.8 on days 1, 2, and 7 after SLED, respectively (P < 0.01). Three patients died on days 1, 3, and 4 after SLED, respectively. The remaining twelve patients were either cured or showed improvement at the time of discharge. The survival rate was 80 % where as mortality was 20 %. SLED may be an effective treatment option in severe snakebite patients. It can reduce mortality, thereby, resulting in increased survival rates. 相似文献